Clinicopathologic features of patients < 40 years with follicular lymphoma (cohort 1)
| . | All patients (n = 27) . | Stage I (n = 21) . | Stage III-IV (n = 6) . | P . |
|---|---|---|---|---|
| Clinical features | ||||
| Median age, y (range) | 18 (8-36) | 17 (8-36) | 23 (17-34) | .03 |
| Age of patient ≥ 18 y | 14/27 (52) | 9/21 (43) | 5/6 (83) | .16 |
| M:F | 22:5 | 18:3 | 4:2 | .58 |
| Histologic features | ||||
| Complete nodal effacement | 18/27 (67) | 14/21 (67) | 4/6 (67) | 1.0 |
| Marginal zone differentiation | 3/27 (11) | 3/21 (14) | 0/6 (0) | 1.0 |
| Follicle size > 2 mm diameter | 15/27 (56) | 14/21 (67) | 1/6 (17) | .06 |
| > 50% “Starry-sky” follicles | 14/27 (52) | 13/21 (62) | 1/6 (17) | .08 |
| Histologic grade 3A | 10/27 (37) | 9/21 (43) | 1/6 (17) | .36 |
| Immunophenotypic and genetic features | ||||
| BCL2+ tumor cells (≥ 2+ intensity) | 14/27 (52) | 8/21 (38) | 6/6 (100) | .02 |
| BCL2 gene rearrangement | 5/27 (19) | 0/21 (0) | 5/6 (83) | < .0001 |
| Median Ki67 PI (range) | 65% (5%-95%) | 70% (40%-95%) | 25% (10%-70%) | .008 |
| Ki67 PI < 30% | 3/27 (11) | 0/21 (0) | 3/6 (50) | .007 |
| Ki67 PI < 30% or BCL2 gene rearrangement | 6/27 (22) | 0/21 (0) | 6/6 (100) | < .0001 |
| Treatment | ||||
| Excision only | 14/27 (52) | 14/21 (67) | 0/6 (0) | ND |
| Radiation therapy only | 1/27 (4) | 1/21 (5) | 0/6 (0) | |
| Chemotherapy | 12/27 (44) | 6/21 (28) | 6/6 (100)* | |
| Outcome | ||||
| Relapse or progression | 5/27 (19) | 0/21 (0) | 5/6 (83) | < .0001 |
| Persistent disease at latest follow-up | 3/27 (11) | 0/21 (0) | 3/6 (50) | .007 |
| Died from disease | 1/27 (4) | 0/21 (0) | 1/6 (17) | .22 |
| . | All patients (n = 27) . | Stage I (n = 21) . | Stage III-IV (n = 6) . | P . |
|---|---|---|---|---|
| Clinical features | ||||
| Median age, y (range) | 18 (8-36) | 17 (8-36) | 23 (17-34) | .03 |
| Age of patient ≥ 18 y | 14/27 (52) | 9/21 (43) | 5/6 (83) | .16 |
| M:F | 22:5 | 18:3 | 4:2 | .58 |
| Histologic features | ||||
| Complete nodal effacement | 18/27 (67) | 14/21 (67) | 4/6 (67) | 1.0 |
| Marginal zone differentiation | 3/27 (11) | 3/21 (14) | 0/6 (0) | 1.0 |
| Follicle size > 2 mm diameter | 15/27 (56) | 14/21 (67) | 1/6 (17) | .06 |
| > 50% “Starry-sky” follicles | 14/27 (52) | 13/21 (62) | 1/6 (17) | .08 |
| Histologic grade 3A | 10/27 (37) | 9/21 (43) | 1/6 (17) | .36 |
| Immunophenotypic and genetic features | ||||
| BCL2+ tumor cells (≥ 2+ intensity) | 14/27 (52) | 8/21 (38) | 6/6 (100) | .02 |
| BCL2 gene rearrangement | 5/27 (19) | 0/21 (0) | 5/6 (83) | < .0001 |
| Median Ki67 PI (range) | 65% (5%-95%) | 70% (40%-95%) | 25% (10%-70%) | .008 |
| Ki67 PI < 30% | 3/27 (11) | 0/21 (0) | 3/6 (50) | .007 |
| Ki67 PI < 30% or BCL2 gene rearrangement | 6/27 (22) | 0/21 (0) | 6/6 (100) | < .0001 |
| Treatment | ||||
| Excision only | 14/27 (52) | 14/21 (67) | 0/6 (0) | ND |
| Radiation therapy only | 1/27 (4) | 1/21 (5) | 0/6 (0) | |
| Chemotherapy | 12/27 (44) | 6/21 (28) | 6/6 (100)* | |
| Outcome | ||||
| Relapse or progression | 5/27 (19) | 0/21 (0) | 5/6 (83) | < .0001 |
| Persistent disease at latest follow-up | 3/27 (11) | 0/21 (0) | 3/6 (50) | .007 |
| Died from disease | 1/27 (4) | 0/21 (0) | 1/6 (17) | .22 |
Values are no. (%) unless otherwise noted.
ND indicates not done; and PI, proliferation index.
Followed by an initial period of observation (10 and 32 mo) in 2 patients.